Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998048813) METHODS FOR USING MACROCYCLIC LACTONE COMPOUNDS AS MULTIDRUG RESISTANCE REVERSING AGENTS IN TUMOR AND OTHER CELLS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/048813 International Application No.: PCT/IB1998/000750
Publication Date: 05.11.1998 International Filing Date: 29.04.1998
Chapter 2 Demand Filed: 19.11.1998
IPC:
A61K 31/365 (2006.01) ,A61K 31/475 (2006.01) ,A61K 38/08 (2006.01) ,A61K 38/12 (2006.01) ,A61K 45/06 (2006.01) ,C07D 493/22 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
365
Lactones
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
475
having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08
Peptides having 5 to 11 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12
Cyclic peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
22
in which the condensed system contains four or more hetero rings
Applicants:
MCGILL UNIVERSITY [CA/CA]; 845 Sherbrooke Street W. Montreal, Quebec H3A 2T5, CA
Inventors:
PRICHARD, Roger, K.; CA
POULIOT, Jean-François; CA
GEORGES, Elias; CA
Agent:
CONN, David, L. ; Smart & Biggar 900 - 55 Metcalfe Street P.O. Box 2999, Station D Ottawa, Ontario K1P 5Y6, CA
Priority Data:
09/067,67728.04.1998US
60/045,16130.04.1997US
Title (EN) METHODS FOR USING MACROCYCLIC LACTONE COMPOUNDS AS MULTIDRUG RESISTANCE REVERSING AGENTS IN TUMOR AND OTHER CELLS
(FR) PROCEDES D'UTILISATION DE COMPOSES DE LACTONE MACROCYCLIQUES EN QUALITE D'AGENTS D'INVERSION DE LA RESISTANCE AUX MEDICAMENTS POLYVALENTS DANS DES CELLULES CANCEREUSES ET AUTRES
Abstract:
(EN) This invention describes methods for increasing the toxicity of a cytostatic hydrophobic chemotherapeutic agent against resistant tumor cells which comprise administering to a mammal an effective amount of a multidrug resistant reversing agent, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound. Examples of macrocyclic lactone compounds useful in the present invention include, but are not limited to, the LL-F28249$g(a)-$g(l) series, the 23-oxo or 23-imino derivatives thereof, the avermectings, the 22,23-dihydro derivatives thereof and the milbemycins. Compositions comprising the macrocyclic lactone compounds and the chemotherapeutic agents are also described herein.
(FR) Cette invention concerne des procédés permettant d'accroître la toxicité d'un agent de chimiothérapie hydrophobe et cytostatique contre les cellules cancéreuses résistantes. Ce procédé consiste à administrer à un mammifère une quantité efficace d'un agent d'inversion de la résistance aux médicaments polyvalents, agent qui consiste en un composé de lactone macrocyclique. Parmi les exemples de composés de lactone macrocycliques utiles et faisant l'objet de cette invention, on peut citer la série LL-F28249$g(a)-$g(l), les dérivés 22-oxo ou 23-imino de celle-ci, les avermectines, les dérivés 22,23-dihydro de celles-ci ainsi que les milbémycines. Cette invention concerne également des compositions comprenant ces composés de lactone macrocycliques, ainsi que des agents de chimiothérapie.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
MXPA/a/1999/009997EP0979089CA2289086NZ500429AU1998070736DK0979089